Clyde Biosciences Announces £2m 'Series A' Investment

Released: Thursday 16th April 2015

A UNIVERSITY of Glasgow spin-out behind pioneering technology to evaluate drug toxicity and improve patient safety has been boosted by a £2 million investment.


The funding for Clyde Biosciences is led by Epidarex Capital, a venture capital fund focused on early-stage life sciences firms, with backing also coming from the Scottish Investment Bank and Glasgow University Holdings. 

Click on the link for the full story at Herald Scotland

View all News